Filing Details
- Accession Number:
- 0001209191-23-046243
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-17 16:10:57
- Reporting Period:
- 2023-08-15
- Accepted Time:
- 2023-08-17 16:10:57
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1719395 | Eargo Inc. | EAR | Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) | 273879804 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1827198 | Adam Laponis | C/O Eargo, Inc. 2665 North First Street, Suite 300 San Jose CA 95134 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-08-17 | 19 | $3.24 | 3,152 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2023-08-15 | 97,500 | $0.00 | 97,500 | $3.31 |
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2023-08-15 | 82,500 | $0.00 | 82,500 | $3.31 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-15 | 82,500 | $0.00 | 82,500 | $11.58 |
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2023-08-15 | 82,500 | $0.00 | 82,500 | $3.31 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-15 | 82,500 | $0.00 | 82,500 | $11.58 |
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2023-08-15 | 824 | $0.00 | 824 | $3.31 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-15 | 824 | $0.00 | 824 | $1,051.60 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
97,500 | 2033-08-14 | No | 4 | A | Direct | |
82,500 | 2033-01-31 | No | 4 | A | Direct | |
0 | 2033-01-31 | No | 4 | D | Direct | |
82,500 | 2033-01-31 | No | 4 | A | Direct | |
0 | 2033-01-31 | No | 4 | D | Direct | |
824 | 2031-01-28 | No | 4 | A | Direct | |
0 | 2031-01-28 | No | 4 | D | Direct |
Footnotes
- Reflects the number of shares of Common Stock that were sold to satisfy tax withholding requirements on vesting of restricted stock units pursuant to the Issuer's automatic sell to cover program, and does not represent a discretionary sale by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $3.23 to $3.24, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the shares of Common Stock sold at each separate price within the range set forth in this footnote.
- The Stock Option vests and becomes exercisable in 8 equal quarterly installments, with the first installment vesting on November 15, 2023, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
- The Issuer cancelled the Stock Option in exchange for a new option having a lower exercise price.
- The Stock Option vests and becomes exercisable as to 20% of the shares subject to the stock option on February 15, 2024 (the "Vesting Start Date"), with the remainder vesting in 16 equal quarterly installments thereafter until all of the shares subject to the stock option have vested and become exercisable on the fourth anniversary of the Vesting Start Date, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
- The Stock Option vests and becomes exercisable in 8 equal quarterly installments, with the first installment vesting on November 15, 2023, provided, that, any unvested portion of the Stock Option shall vest and become exercisable upon attainment of a 360-day VWAP (volume weighted average price) of $20.00 for the Issuer's Common Stock, in either case, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
- The Stock Option vests and becomes exercisable in full upon attainment of a 360-day VWAP (volume-weighted average price) of $20.00 for the Issuer's Common Stock on or prior to February 15, 2028, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through such date.
- The Stock Option shall vest and become exercisable with respect to 16 quarterly installments commencing on February 15, 2021, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
- On January 17, 2023, the Issuer effected a 1-for-20 reverse stock split of its Common Stock (the "Reverse Stock Split"). These securities reflect the Reverse Stock Split.